Anthropometric and biochemical assessment of schizophrenic patients taking clozapine;Avaliação antropométrica e bioquímica em pacientes com esquizofrenia usuários de clozapina

Revista de Nutricao

Volumn 22, Issue 5, 2009, Pages 697-705

  Zortéa, Karine ^a   Bock, Patrícia Martins ^b   Moreno, Dolores Benites ^a   de Abreu, Paulo Silva Belmonte ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^b CENTRO UNIVERSITÁRIO METODISTA IPA   (Brazil)

Author keywords

Clozapine; Obesity; Schizophrenia

Indexed keywords

EID: 77949339195     PISSN: 14155273     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1415-52732009000500010     Document Type: Article

References (33)

1. Manual Diagnóstico e Estatístico de Transtornos Mentais-DSM-IV-TR. 4a. ed. Porto Alegre: Artmed; 2003.
2. Organização Mundial da Saúde. Classificação de transtornos mentais e de comportamento da CID-10: descrições clínicas e diretrizes diagnósticas. Porto Alegre: Artmed; 1993.
3. Mari JJ, Leitão RJ. A epidemiologia da esquizofrenia. Rev Bras Psiquiatr. 2000; 22(1):15-7. doi: 10.1590/S1516-44462000000500006.
4. Rang HP, Dale MM, Ritter JM, Moore PK. Farmacologia. 5a. ed. Rio de Janeiro: Elsevier; 2004.
5. Kaplan HI. Compêndio de psiquiatria: ciências do comportamento e psiquiatria clínica. 7a. ed. Porto Alegre: Artmed; 1997.
6. Chaves AC. Diferenças entre os sexos na esquizofrenia. Rev Bras Psiquiatr. 2000; 22(1):21-2. doi: 10.1590/S1516-44462000000500008.
7. Gama CS, Souza CM, Lobato MI, Abreu PSB. Clozapine use report in 56 patients seen by Clerkship of Health and Environment of the State of Rio Grande do Sul's Program of Attention to the Refractory Schizophrenia. Rev Psiquiatr Rio Grande Sul. 2004; 26(1):21-8. doi: 10.1590/ S0101-81082004000100004.
8. Morais RMO, Oliveira IR. Antipsicóticos. In: Silva P. Farmacologia. 7a. ed. Rio de Janeiro: Guanabara Koogan; 2006.
9. Casey DE. Dyslipidemia and atypical antipsychotis drugs. J Clin Psychiatry. 2004; 65(18):27-35.
10. Lewis SW, Barnes TRE, Davies L, Murray RM, Dunn G, Hayhurst KP, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull. 2006; 32(4): 715-23.
11. Meltzer, HY. Putting metabolic side effects into perspective: risks versus benefits of atypical antipsychotics. J Clin Psychiatry. 2001; 62(27):35-9.
12. Munoz P, Gallardo R. Transtornos metabólicos en pacientes esquizofrênicos tratados con clozapina. Rev Chil de Neuro-Psiquiatr. 2004; 42(1):37-42. doi: 10.4067/S0717-92272004000100005.
13. Brasil. I Diretriz Brasileira de Diagnóstico e Tratamento da Síndrome Metabólica. Arq Bras Cardiol. 2005; 84(1):3-28. doi: 10.1590/S0066-782X2005 000700001.
14. Duncan BB, Schmidt MI. Chronic activation of the innate immune system may underlie the metabolic syndrome. São Paulo J Med. 2001; 119(3):122-7. doi:.10.1590/S1516-31802001000300008.
15. Goff DC, Cather C, Evins AE, Henderson DC, Freudenreich O, Copeland PM, et al. Medical morbidity and mortality in Schizophrenia: guidelines for psychiatrists. J Clin Psychiatry. 2005; 66(2):183-93.
16. World Health Organization. Physical status: the use and interpretation of anthropometry. Genebra: WHO; 1998.
17. Brasil. IV Diretriz Brasileira Sobre as Dislipidemias e Prevenção da Aterosclerose do Departamento de Aterosclerose da Sociedade Brasileira de Cardiologia. Arq Bras Cardiol. 2007; 88(1)2-19. doi:.10.1590/S0066-782X2007000700002.
18. Lohman TG. Advances in body composition assessment. Current issues in exercise science series. Monografh n.3. Champaign (IL): Human Kinetics; 1992.
19. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP). Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285(19): 2486-97.
20. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care. 2005; 28(1):4-36.
21. Brasil. Ministério da Saúde. Guia alimentar para a população brasileira: promovendo a alimentação saudável. Brasília; 2006.
22. Souza VBN, Guedes ARA. Índice de massa corpórea de esquizofrênicos em uso de antipsicóticos típicos e atípicos. Neurobiologia. 2002; 65(1):77-80.
23. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry. 2000; 157(6):975-81.
24. Cercato C, Mancini MC, Arguello AMC, Passos VQ, Villares SMF, Halpern A. Systemic hypertension, diabetes mellitus, and dyslipidemia in relation to body mass index: evaluation of a Brazilian population. Rev Hosp Clin. 2004; 59(3):113-8. doi: 10.1590/S0041-87812004000300004.
25. Bustillo JR, Buchanan Robert W, Irish D, Breier A. Differential effect of Clozapine on weight: a controlled study. Am J Psychiatry.1996; 153(6): 817-9.
26. Allison DB, Mentore JL, Ed MS, Heo M, Chandler LP, Cappelleri JC, et al. Antipsychotics-induced weight-gain: a comprehensive research synthesis. Am J Psychiatry. 1999; 156(11):1686-9.
27. Teixeira PJR, Rocha FL. Efeitos adversos metabólicos de antipsicóticos e estabilizadores de humor. Rev Psiquiatr Rio Grande do Sul. 2006; 28(2):186-96. doi: 10.1590/S0101-81082006000200011.
28. Kivircik BB, Alptekin K, Çaliskan S, Çomlejçi A, Oruk G, Tumuklu M, et al. Effect of clozapine on serum leptin, insulin levels, and body weight and composition in patients with schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry. 2003; 27(5):795-9.
29. Wu MK, Huang CY, Liou YJ, Wang CK, Lee SD. Glucose-insulin homeostasis, lipid profiles and GH-IGF-IGFBP axis in clozapine-treated schizophrenic obesity versus non-psychiatric obesity. Int J Obes. 2008; 32(3):436-42. doi:10.1038/sj.ijo.0803750.
30. Leon, J, Diaz FJ, Josiassen RC, Cooper TB, Simpson GM. Weight gain during a double-blind multidosage Clozapine study. J Clin Psychopharmacol. 2007; 27(1):22-7.
31. Baymiller SP, Ball P, McMahon RP, Buchanan RW. Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment. Schizophr Res. 2003; 59(1):49-57.
32. De Hert, M, Peuskens B, Winkel RV, Kalnicka D, Hanssens L, Eyck DV, et al. Body weight and selfesteem in patients with schizophrenia evaluated with B-WISE(. Schizophr Res. 2006; 88(1-3): 222-6.
33. McIntyre RS. Mechanisms of antipsychotic-induced weight gain. J Clin Psychiatry. 2001; 62(23):23-9.